ORLANDO, Fla. — January 30, 2026 — Leads & Copy — Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) has released an update to shareholders following its Annual Shareholders Meeting, which took place on January 24, 2026, in Orlando, Florida.
The update includes details on the addition of two new directors, Alessandro Puddu and Viorica Carlig.
Puddu is an Italian Chartered Accountant and Statutory Auditor with over 10 years of experience in audit, corporate advisory, and financial reporting for industrial groups and listed companies. He advises on tax and corporate matters, company valuations, and IAS/IFRS reporting. He also serves as Group Internal Auditor for an Italian Stock Exchange-listed company.
Carlig is a senior executive with over a decade of leadership experience across service-based companies. She provides executive and strategic oversight for multiple multinational organizations, with a background spanning business administration, law, and economics.
The company also provided a summary of the 2025 AVERSA™ FENTANYL development, which included a strengthened collaboration with Kindeva for AVERSA™ FENTANYL through an exclusive product development partnership and long-term commitment based on shared development costs in exchange for milestone payments.
Nutriband also was granted a patent protecting its AVERSA™ abuse deterrent platform technology in Macao, a Special Administrative Region of the People’s Republic of China, and completed commercial manufacturing process scale-up with partner Kindeva for Aversa™ Fentanyl. The company was also issued a new US patent further expands Nutriband’s intellectual property protection in the United States for its portfolio of abuse deterrent transdermal products.
The company held a Type C meeting with US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for AVERSA™ FENTANYL through commercialization and filed a new provisional patent application with the U.S. Patent and Trademark Office (USPTO) covering improved aversive formulations and coating application methods to enhance the abuse deterrent properties and further strengthen Nutriband’s intellectual property protection for its AVERSA™ technology. Nutriband also initiated development of the worldwide commercial brand name and visual identity for AVERSA™ FENTANYL with Brand Institute, Inc.
Nutriband’s 2026 focus will be on AVERSA™ FENTANYL development towards NDA filing, including filing a nonprovisional patent application to potentially extend patent protection of AVERSA™ technology-based products to 2046 and manufacture clinical supplies for the Human Abuse Liability (HAL) clinical trial.
The company also plans to file an Investigational New Drug (IND) application with the US FDA and initiate a Human Abuse Liability (HAL) clinical study.
Regarding the EarthVision Bio purchase of Pocono Pharma, the full purchase price and closing for the proposed sale of the Pocono subsidiary has not been received as of the shareholder meeting on Jan 24, 2026. However, the Company is collecting on the agreed nonrefundable $10,000 USD weekly penalty and has so far collected $30,000 USD of payments to extend the closing date.
Nutriband has filed a complaint with the Financial Industry Regulatory Authority (FINRA) on behalf of shareholders to investigate suspected naked short selling. The information was collected and prepared with a specialist analyst.
The company is reminding shareholders that the warrants issued in their uplisting to NASDAQ on October 1, 2021, will expire on October 1, 2026. Currently, there are 91,0904 warrants set to expire with a strike price of $6.43 totaling $5,856,112 if exercised.
Nutriband’s AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential.
The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Source: Nutriband Inc.
